Business Wire

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System

30.1.2026 08:30:00 CET | Business Wire | Press release

Share

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine.

In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market.

Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinical research. With over 3,000 peer- reviewed and published articles, the company currently has 32 ongoing global clinical study projects enrolling 600+ patients with over 2,000 study visits, treating a wide range of skin types and conditions.

The launch of the Glacē system, together with the upcoming launch of the Matrix and VBeam Pro systems, provides best-in-class treatment solutions for skin health including skin tightening, texture, acne, scars, advanced vascular treatments and overall skin quality.

The Glacē System is a professional facial system designed for high-frequency skin care for medical, wellness and aesthetic providers. Engineered as a comprehensive skin purifying platform, the Glacē system functions both as a standalone facial treatment and as a clinically proven adjunct to energy-based device treatments to support improved skin quality, patient comfort and consistent results. The Glacē system enables a broader segment of practices — spanning the range from beauty-focused to medical aesthetic practices, to offer a modern, repeatable skin health treatment while enhancing combination treatment outcomes for practices using Candela devices.

The Matrix System (currently pending EU MDR clearance) is Candela’s next-generation skin renewal workstation that combines intelligent, outcomes-driven energy delivery with safety-by-design engineering. The multiapplication radiofrequency (RF) platform integrates skin resurfacing, microneedling and noninvasive wrinkle treatment within a single device to address multiple layers of the skin with precision. Powered by Candela’s signature Aesthetic Intelligence technology, the Matrix system is designed to sense, adapt and display tissue impedance in real time, supporting safe, smooth and consistent heating across applications, skin types and depths. This intelligent performance allows providers to deliver reproducible outcomes across all skin types and a wide range of indications, notably skin tightening, acne scarring, textural irregularities and collagen loss.

The Vbeam Pro system, launched in 2025 in the U.S., is the only vascular laser FDA-cleared for use in pediatric patients. It combines an advanced 595 nm pulsed dye laser with a 1064 nm Nd:YAG wavelength to offer unmatched precision, accuracy and treatment versatility. The platform is designed to effectively treat a broad spectrum of skin conditions, including pediatric and adult vascular abnormalities, rosacea, port-wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks, and photoaging.

“Developing innovative products that powerfully enhance skin health and youthfulness is our passion. We are excited to be unveiling the Matrix, Glacē and VBeam Pro systems here,” said Geoffrey Crouse, Chief Executive Officer of Candela. “By launching these major platforms, we are accelerating our ability to serve customers in the fast-evolving European and global market, where patient demand continues to grow, and our scientific and clinically proven treatment solutions continue to uniquely address skin quality, laxity, texture, tone and more.”

As part of this next chapter of innovation, Candela is also unveiling experience-driven customer engagement — pairing scientific exchange with immersive brand experience designed to foster engagement with key opinion leaders, partners and customers, including exclusive clinical and customer experiences held in conjunction with IMCAS.

“As someone whose practices use both the Glacē and Matrix systems, I see these platforms as highly complementary,” said Firas Al-Niaimi, MD, Professor of Laser Dermatology and a Board-Certified Dermatologist with a private practice in London. “Together, they allow us to comprehensively address skin health — including skin laxity, texture and tone — safely with precision and confidence. Candela continues to invest not only in technology, but also in addressing the needs of a broader cross-section of aesthetic practices and their patients in clinically validated ways that meaningfully and positively impact our patient experience.”

Candela will showcase the Glacē, Matrix and VbeamPro Systemsat IMCAS 2026, featuring live product demonstrations, scientific presentations, a dedicated symposium on Epigenetics and Skin Health, and other engagement opportunities with its global clinical community.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260129455611/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release

Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other

Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release

QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye